Major depressive disorder (MDD) is the most prevalent and severe form of mental illness and is significantly linked to suicide. At present, addressing the treatment and prevention of depression and suicide poses significant challenges, largely due to...
Cognitive behavioral therapy (CBT) and pharmacotherapy are primary treatments for major depressive disorder (MDD). However, their differential effects on the neural networks associated with rumination, or repetitive negative thinking, remain poorly u...
BACKGROUND: Anhedonia, a transdiagnostic feature common to both Major Depressive Disorder (MDD) and Schizophrenia (SCZ), is characterized by abnormalities in hedonic experience. Previous studies have used machine learning (ML) algorithms without focu...
Deep learning techniques have demonstrated significant promise for detecting Major Depressive Disorder (MDD) from textual data but they still face limitations in real-world scenarios. Specifically, given the limited data availability, some efforts ha...
Psychosis poses substantial social and healthcare burdens. The analysis of speech is a promising approach for the diagnosis and monitoring of psychosis, capturing symptoms like thought disorder and flattened affect. Recent advancements in Natural Lan...
Major Depressive Disorder is the most prominent global mental health issue impacting millions of individuals worldwide. Electroencephalogram signals capturing intricate brain dynamics have emerged as a promising modality for predicting depression. Th...
INTRODUCTION: The role of non-suicidal self-injury (NSSI) in the suicide process of people with major depressive disorder(MDD) remains controversial. Therefore, the purpose of this study was to investigate the role NSSI plays in suicide risk in peopl...
BACKGROUND: Major depressive disorder (MDD) is a prevalent and severe psychiatric condition for which objective diagnostic tools are lacking. Heart rate variability (HRV), an index of autonomic nervous system (ANS) function, has shown potential for d...
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Jun 17, 2025
Nearly 60 % of individuals with bipolar disorder (BD) are initially classified as major depressive disorder (MDD) patients, resulting in inappropriate drug treatment. Identifying reliable biomarkers for the differential diagnosis between MDD and BD p...
AIMS: The efficacy of cariprazine for major depressive disorder (MDD) (adjunctive therapy) and bipolar I (BP-I) depression has been demonstrated in clinical trials. This study evaluated the real-world effectiveness of cariprazine in reducing depressi...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.